Ying Zhu

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 245 citations

Interim Analysis, Lymphoid Neoplasia, Medicine +8

KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer

Ken Kato, Manish A. Shah, Peter C. Enzinger et al. · Future Oncology · 2019 · 168 citations · Full text

Esophageal Cancer, Immunology, Gastroenterology +16

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia

Joseph M. Flynn, Jeffrey A. Jones, Amy J. Johnson et al. · Leukemia · 2015 · 114 citations · Full text

Oncology, Medicine, Receptor Tyrosine Kinase +7

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

Philippe Armand, John Kuruvilla, Jean‐Marie Michot et al. · Blood Advances · 2020 · 51 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Transplantation +15

RETRACTED: CD133+/CD44+/Oct4+/Nestin+ stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer

Dongqing Wang, Haitao Zhu, Ying Zhu et al. · Acta Histochemica · 2012 · 40 citations

Tumor Biology, Pancreatic Cancer, Medicine +8